- Home
- MDAI vs INKT Comparison
MDAI vs INKT Comparison
Compare MDAI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDAI | INKT |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.8M | 52.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDAI | INKT |
|---|---|---|
| Price | $1.75 | $10.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 160.6K | 10.4K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $8.48 |
| 52 Week High | $2.97 | $18.17 |
Technical Indicators
Market Signals| Indicator | MDAI | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 49.90 |
| Support Level | $1.62 | $10.72 |
| Resistance Level | $1.77 | $11.62 |
| Average True Range (ATR) | 0.07 | 0.55 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 80.00 | 44.89 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.